Quest Pharmatech Inc (QPTFF) 0.0380 $QPTFF
Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 13.66 (+0.65), SPHS: 0.78 (+0.03), NYMX: 1.25 (+0.05), ABBV: 69.23 (+1.26)
Quest PharmaTech Announces Funding Support from National Research Council's Industrial Research Assistance Program for IgE Antibody Cancer Immunotherapy Development (AllergoOncology)
PR Newswire - Tue Jan 13, 8:30AM CST
TSX Venture: QPT
QPT.VN: 0.040 (unch)
Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.78 (+0.03), AEZS: 0.24 (+0.01), NYMX: 1.25 (+0.05)
Acne Vulgaris - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/9twpcx/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim - Photocure - Valeant Pharmaceuticals International - GlaxoSmithKline - Photopharmica - Galderma - Toyama Chemical - AntiCancer - XOMA Corporation - Quest PharmaTech - Provectus Biopharmaceuticals - Phosphagenics - Foamix - AndroScience - Hygeia Therapeutics - ELORAC - Cutanea Life Sciences - Braintree Laboratories - Maruho - Sol-Gel Technologies - Ensoltek - Ausio Pharmaceuticals - XBiotech USA - Advancell - Delenex Therapeutics - Dermira - Dignity Sciences - Biomar Microbial Technologies - Thesan Pharmaceuticals - OrigImm For more information visit http://www.researchandmarkets.com/research/9t...e_vulgaris
PVCT: 0.51 (+0.01), GSK: 42.45 (+0.65), XOMA: 4.72 (+0.23), VRX.TO: 294.65 (+11.22)
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creator of COLD FX®, to Assist
PR Newswire - Wed Oct 22, 12:34PM CDT
TSX Venture: QPT
QPT.VN: 0.040 (unch)
Quest PharmaTech Signs License Agreement With Bioceltran Co., Ltd. for Photodynamic Therapy Technology
Marketwire - Thu Oct 02, 8:02AM CDT
Quest PharmaTech Inc. (TSX VENTURE: QPT) ("Quest" or the "Company"
, a pharmaceutical company developing and commercializing products for the treatment of cancer, reports today that it has signed a license agreement with Bioceltran Co., Ltd. (Bioceltran), a private South Korean based company focused on Protein Transduction Domain (PTD) Technology for transdermal delivery of drugs for cosmetics and pharmaceuticals, to license Quest's photodynamic therapy (PDT) technology to Bioceltran in return for up-front license fees, milestone payments and royalties on future product sales.
QPT.VN: 0.040 (unch)
Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 13.66 (+0.65), SPHS: 0.78 (+0.03), NYMX: 1.25 (+0.05), ABBV: 69.23 (+1.26)
Quest PharmaTech Announces Funding Support from National Research Council's Industrial Research Assistance Program for IgE Antibody Cancer Immunotherapy Development (AllergoOncology)
PR Newswire - Tue Jan 13, 8:30AM CST
TSX Venture: QPT
QPT.VN: 0.040 (unch)
Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.78 (+0.03), AEZS: 0.24 (+0.01), NYMX: 1.25 (+0.05)
Acne Vulgaris - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/9twpcx/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim - Photocure - Valeant Pharmaceuticals International - GlaxoSmithKline - Photopharmica - Galderma - Toyama Chemical - AntiCancer - XOMA Corporation - Quest PharmaTech - Provectus Biopharmaceuticals - Phosphagenics - Foamix - AndroScience - Hygeia Therapeutics - ELORAC - Cutanea Life Sciences - Braintree Laboratories - Maruho - Sol-Gel Technologies - Ensoltek - Ausio Pharmaceuticals - XBiotech USA - Advancell - Delenex Therapeutics - Dermira - Dignity Sciences - Biomar Microbial Technologies - Thesan Pharmaceuticals - OrigImm For more information visit http://www.researchandmarkets.com/research/9t...e_vulgaris
PVCT: 0.51 (+0.01), GSK: 42.45 (+0.65), XOMA: 4.72 (+0.23), VRX.TO: 294.65 (+11.22)
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creator of COLD FX®, to Assist
PR Newswire - Wed Oct 22, 12:34PM CDT
TSX Venture: QPT
QPT.VN: 0.040 (unch)
Quest PharmaTech Signs License Agreement With Bioceltran Co., Ltd. for Photodynamic Therapy Technology
Marketwire - Thu Oct 02, 8:02AM CDT
Quest PharmaTech Inc. (TSX VENTURE: QPT) ("Quest" or the "Company"
, a pharmaceutical company developing and commercializing products for the treatment of cancer, reports today that it has signed a license agreement with Bioceltran Co., Ltd. (Bioceltran), a private South Korean based company focused on Protein Transduction Domain (PTD) Technology for transdermal delivery of drugs for cosmetics and pharmaceuticals, to license Quest's photodynamic therapy (PDT) technology to Bioceltran in return for up-front license fees, milestone payments and royalties on future product sales. QPT.VN: 0.040 (unch)
